Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
RPRX
Royalty Pharma plc C
$32.88
Chart
$32.19 (+2.14%)
$33.01 (-0.39%)
$30.62 (+7.38%)
$26.92 (+22.14%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
RPRX
Royalty Pharma plc C
Current Price
$32.88
Login to view Royalty Pharma plc C (RPRX) recommendation from the last 90 days from financial news and social media.
Chart
$32.19 (+2.14%)
$33.01 (-0.39%)
$30.62 (+7.38%)
$26.92 (+22.14%)
RPRX Latest Headlines
Royalty Pharma Completes the Acquisition of Its External Manager. NEW YORK May 16 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager RP Management LLC (RP Management). The acquisition received overwhelming support from Royalty Pharmas shareholders with 99.9% of votes cast in favor of the transaction.
Fri May 16, 2025
Royalty Pharma Completes the Acquisition of Its External Manager. NEW YORK May 16 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager RP Management LLC (RP Management). The acquisition received overwhelming support from Royalty Pharmas shareholders with 99.9% of votes cast in favor of the transaction.
Fri May 16, 2025
Ex-Dividend Reminder: Eli Lilly Cencora and Royalty Pharma . Looking at the universe of stocks we cover at Dividend Channel on 5/16/25 Eli Lilly (Symbol: LLY) Cencora Inc (Symbol: COR) and Royalty Pharma plc (Symbol: RPRX) will all trade ex-dividend for their respective upcoming dividends. Eli Lilly will pay its quarterly dividend of
Wed May 14, 2025
Royalty Pharma to Present at Upcoming Investor Conferences. NEW YORK May 13 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Tue May 13, 2025
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition . NEW YORK May 12 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition with 99.9% voting in favor at Royalty Pharmas 2025 Annual General Meeting and Special Meeting of Shareholders (the Meeting) marking a key milestone for the company.
Mon May 12, 2025
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition . NEW YORK May 12 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition with 99.9% voting in favor at Royalty Pharmas 2025 Annual General Meeting and Special Meeting of Shareholders (the Meeting) marking a key milestone for the company.
Mon May 12, 2025
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition . NEW YORK May 12 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition with 99.9% voting in favor at Royalty Pharmas 2025 Annual General Meeting and Special Meeting of Shareholders (the Meeting) marking a key milestone for the company.
Mon May 12, 2025
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition . NEW YORK May 12 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition with 99.9% voting in favor at Royalty Pharmas 2025 Annual General Meeting and Special Meeting of Shareholders (the Meeting) marking a key milestone for the company.
Mon May 12, 2025
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition . NEW YORK May 12 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition with 99.9% voting in favor at Royalty Pharmas 2025 Annual General Meeting and Special Meeting of Shareholders (the Meeting) marking a key milestone for the company.
Mon May 12, 2025
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition . NEW YORK May 12 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition with 99.9% voting in favor at Royalty Pharmas 2025 Annual General Meeting and Special Meeting of Shareholders (the Meeting) marking a key milestone for the company.
Mon May 12, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
RPRX Stock trends
RPRX Stock performance
RPRX Stock analysis
RPRX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Latest Updates
Hover over the category for more information
